Skip to main content

Women at Risk for Pregnancy

3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sebela Pharmaceuticals
2 programs
2
VeraCeptPhase 3
VeraCeptPhase 31 trial
Active Trials
NCT03785366Completed41Est. Aug 2024
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
VeraCeptPhase 31 trial
Active Trials
NCT03633799Active Not Recruiting1,620Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Sebela PharmaceuticalsVeraCept
Syneos HealthVeraCept

Clinical Trials (2)

Total enrollment: 1,661 patients across 2 trials

A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)

Start: Dec 2018Est. completion: Aug 202441 patients
Phase 3Completed

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

Start: Aug 2018Est. completion: Sep 20271,620 patients
Phase 3Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.